CND Life Sciences
Develops an accurate, evidence-based tool that helps confirm a diagnosis of synucleinopathy.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 Valuation: €0.0 5.4x EV/Revenue | round | |
| N/A | €0.0 Valuation: €0.0 | round | |
* | $13.5m | Series A | |
| Total Funding | 000k | ||
| USD | 2021 | 2022 | 2023 |
|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 |
| % growth | - | 150 % | 53 % |
| EBITDA | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 |
Source: Dealroom estimates
Related Content
CND Life Sciences is a medical technology company that has developed the Syn-One Test, the first commercially available test to detect phosphorylated alpha-synuclein in skin biopsies. This aids in the diagnosis of synucleinopathies, a group of neurodegenerative diseases that includes Parkinson's disease and dementia with Lewy bodies.
The company provides clinicians with a diagnostic tool that offers objective pathological evidence, which can be particularly valuable for diseases that are challenging to diagnose. The process involves a physician collecting three small skin biopsies from the patient using CND's Skin Biopsy Test Kit. These samples are then sent to CND's laboratory for analysis.
CND Life Sciences operates in the neurodiagnostics market, serving neurologists and other healthcare providers. The company's business model is based on the sale of its diagnostic test services. CND Life Sciences has secured funding to support its commercial expansion and further research, including a grant from The Michael J. Fox Foundation to study the quantification of pathological alpha-synuclein.
Keywords: neurodiagnostics, medical technology, diagnostic tests, Parkinson's disease, dementia with Lewy bodies, synucleinopathies, skin biopsy, alpha-synuclein, pathology, life sciences